00:15:27 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2025-02-26 Bokslutskommuniké 2024
2024-11-13 Kvartalsrapport 2024-Q3
2024-08-14 Kvartalsrapport 2024-Q2
2024-05-30 X-dag ordinarie utdelning SIMRIS B 0.00 SEK
2024-05-29 Årsstämma 2024
2024-05-15 Kvartalsrapport 2024-Q1
2024-04-05 Extra Bolagsstämma 2024
2024-02-28 Bokslutskommuniké 2023
2023-12-20 Extra Bolagsstämma 2023
2023-11-08 Kvartalsrapport 2023-Q3
2023-07-24 Kvartalsrapport 2023-Q2
2023-05-29 Årsstämma 2023
2023-05-16 X-dag ordinarie utdelning SIMRIS B 0.00 SEK
2023-05-08 Kvartalsrapport 2023-Q1
2023-02-15 Bokslutskommuniké 2022
2022-11-09 Kvartalsrapport 2022-Q3
2022-08-17 Kvartalsrapport 2022-Q2
2022-05-16 X-dag ordinarie utdelning SIMRIS B 0.00 SEK
2022-05-13 Kvartalsrapport 2022-Q1
2022-05-13 Årsstämma 2022
2022-04-08 Extra Bolagsstämma 2022
2022-02-16 Bokslutskommuniké 2021
2021-11-10 Kvartalsrapport 2021-Q3
2021-08-18 Kvartalsrapport 2021-Q2
2021-05-10 X-dag ordinarie utdelning SIMRIS B 0.00 SEK
2021-05-07 Årsstämma 2021
2021-05-07 Kvartalsrapport 2021-Q1
2021-02-16 Bokslutskommuniké 2020
2020-11-10 Kvartalsrapport 2020-Q3
2020-08-18 Kvartalsrapport 2020-Q2
2020-06-05 X-dag ordinarie utdelning SIMRIS B 0.00 SEK
2020-06-04 Årsstämma 2020
2020-05-07 Kvartalsrapport 2020-Q1
2020-02-14 Bokslutskommuniké 2019
2019-12-19 Extra Bolagsstämma 2019
2019-11-05 Kvartalsrapport 2019-Q3
2019-08-13 Kvartalsrapport 2019-Q2
2019-05-09 X-dag ordinarie utdelning SIMRIS B 0.00 SEK
2019-05-08 Årsstämma 2019
2019-05-08 Kvartalsrapport 2019-Q1
2019-02-12 Bokslutskommuniké 2018
2018-11-20 Kvartalsrapport 2018-Q3
2018-08-21 Kvartalsrapport 2018-Q2
2018-07-25 Extra Bolagsstämma 2018
2018-05-09 X-dag ordinarie utdelning SIMRIS B 0.00 SEK
2018-05-08 Kvartalsrapport 2018-Q1
2018-05-08 Årsstämma 2018
2018-02-20 Bokslutskommuniké 2017
2017-11-21 Kvartalsrapport 2017-Q3
2017-08-22 Kvartalsrapport 2017-Q2
2017-05-11 Kvartalsrapport 2017-Q1
2017-05-11 Årsstämma 2017
2017-04-22 Bokslutskommuniké 2016
2016-11-11 Kvartalsrapport 2016-Q3
2016-09-21 Extra Bolagsstämma 2016
2016-08-24 Kvartalsrapport 2016-Q2
2016-05-18 Kvartalsrapport 2016-Q1

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHandel & varor
IndustriDagligvaror
Simris Group är ett bioteknikbolag. Bolaget är inriktat mot forskning och utveckling samt tillverkning av bioaktiva ämnen från odlade mikroalger, för tillämpningar inom nutrition, cosmeceuticals och läkemedel. Bolagets teknik ersätter även ohållbara råvaror från hotade arter och känsliga marina ekosystem. Första produkten är omega-3-tillskott som säljs under eget varumärke. Simris Group grundades 2011 och har sitt huvudkontor i Hammenhög.
2023-05-29 11:55:00

Simris Group AB (the "Company") held its annual general meeting on 29 May 2023. The following resolutions were made.

Income statements and balance sheets
The general meeting resolved to adopt the income statement and the balance sheet as well as the consolidated income statement and the consolidated balance sheet for the fiscal year of 2022.

Disposition of the Company’s profit or loss
The general meeting resolved, in accordance with the board of directors’ proposal, that no dividend is paid and that the Company’s funds available for distribution are carried forward.

Discharge from liability
The general meeting resolved to grant discharge from liability to all persons who have had the position of board member or CEO in the Company during 2022.

Election of members of the board of directors and auditors
The general meeting resolved that the board of directors shall consist of four ordinary members without deputies. Magnus Högström, Steven Schapera, Frank Puccio and Robert Quandt were re-elected as members of the board.

The general meeting resolved that the number of auditors shall amount to one without a deputy auditor. Ernst & Young AB was re-elected as auditor for the period until the end of the next annual general meeting.

The general meeting resolved that directors' fees shall be paid in the amount of SEK 140,000 to the chairman of the board and SEK 70,000 to other members of the board who are not employed by the Company. It was further resolved that for any additional work efforts in addition to ordinary board work, board members shall be able to receive consulting fees in line with market practice.

The general meeting also resolved that fees to the Company's auditor shall be paid in accordance with approved invoices.

Amendment of the articles of association
The general meeting resolved to increase the Company's permitted minimum share capital from SEK 6,545,000 to SEK 15,000,000 and to increase the maximum permitted share capital from SEK 26,180,000 to SEK 60,000,000 by amending provision § 4 of the articles of association.

The general meeting further resolved to increase the Company's permitted minimum number of shares in the Company to 180,000,000 shares from 72,250,000 shares and the maximum number of shares to 720,000,000 shares from 301,000,000 shares by amending provision § 5 of the articles of association.

The general meeting also resolved to introduce a new provision § 16 whereby the board of directors may collect proxies according to the procedure set out in Chapter 7, Section 4, second paragraph, of the Swedish Companies Act. And that the board of directors may, prior to a general meeting, decide that shareholders shall be able to exercise their voting rights by post before the general meeting.
 
Finally, the general meeting resolved to amend the articles of association to be bilingual and thus be written both in Swedish and in English.

Authorization for the board of directors to resolve on the issue of shares, warrants and/or convertibles
The general meeting resolved to authorize the board of directors to, on one or more occasions, during the period until the next annual general meeting, decide to increase the Company's share capital. The increase in the share capital may take place through a new issue of series A or series B shares and/or convertibles and/or warrants that entitle the conversion or new subscription of series A or B shares. The board of directors shall be able to decide on such an issue with a deviation from the shareholders' preferential rights and/or with provision for cash payment or set-off. Issuance in accordance with this authorization must take place at the market subscription price. The board of directors shall have the right to determine the conditions in general for the issue in accordance with this authorization and who shall have the right to subscribe for new shares, convertibles and/or warrants.